Related Experiment Video

Updated: Jul 15, 2026

Isolation of Murine Coronary Vascular Smooth Muscle Cells
08:24

Isolation of Murine Coronary Vascular Smooth Muscle Cells

Published on: May 30, 2016

Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment

Sabine C Wolf1, Gabriele Sauter, Jürgen Jobst

  • 1Medical Clinic IV, Department of Hypertension and Renal Failure, Eberhard-Karls-University, Tübingen, Germany. bernhard.brehm@onlinehome.de

International Journal of Cardiology
|May 1, 2007
PubMed
Abstract

Insights

Nebivolol, a third-generation beta-blocker, demonstrated anti-inflammatory effects by downregulating inflammatory mediators in human coronary artery smooth muscle cells. Metoprolol did not show similar anti-atherosclerotic gene expression changes.

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Molecular Biology

Background:

  • Vascular smooth muscle cells (hcaSMC) are crucial in atherogenesis.
  • Targeting hcaSMC inflammation and proliferation may inhibit atherosclerosis.
  • Beta-receptor antagonists are used to manage cardiovascular conditions.

Purpose of the Study:

  • To compare the effects of nebivolol and metoprolol on gene expression in hcaSMC.
  • To investigate the anti-inflammatory and anti-proliferative potential of these beta-blockers.

Main Methods:

  • hcaSMC were treated with nebivolol or metoprolol (10^-5 mol/l) for 72 hours.
  • Gene expression profiling was performed to identify changes in inflammatory and proliferative markers.
  • NF-kappaB activation and monocyte chemoattractant protein 1 (MCP-1) levels were assessed.

Main Results:

  • Nebivolol downregulated genes involved in inflammation (e.g., interleukin-1alpha, TNF-alpha-induced protein 6) and proliferation (e.g., PDGF-A).
  • Metoprolol upregulated inflammatory genes (e.g., interleukin-1alpha, heme oxygenase 1) and had no effect on NF-kappaB.
  • Nebivolol reduced basal NF-kappaB and MCP-1 mRNA and protein levels.

Conclusions:

  • Nebivolol exhibits specific anti-inflammatory properties in hcaSMC.
  • These findings highlight potential anti-atherosclerotic benefits of third-generation beta-blockers like nebivolol compared to older agents such as metoprolol.

More Related Videos

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential07:41

Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential

Published on: January 18, 2019

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro08:28

Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro

Published on: February 15, 2022

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...